In primary GBM, elevated H3K9me3 levels and reduced pan-Ac-H3-bound RRP22 expression further implicate epigenetic dysregulation in tumor progression.106 Targeting EZH2, KDMs, and HDACs offers promising avenues for overcoming treatment resistance and improving therapeutic outcomes. This evidence concerns the gene RASL10A and glioblastoma.